Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–11
Headlines
11
Sources here
1
Companies here
3
Current section Denmark Biotechnology news
Latest

finance.yahoo.com Earnings

Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026

ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK's management will comment on the results for the first …

Provider-linked mention 🇩🇰 Denmark
Read at finance.yahoo.com
Sharemaestro market context Trend signal ended 52 weeks +23.3% ALK-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non-recurring items. This …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Regulatory and legal Main company 🇩🇰 Denmark

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇩🇰 Denmark

Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …

GMAB main company
Sharemaestro market context Price above Trend Line 52 weeks +33.5% GMAB stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context